▲ +116.89% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Verona Pharma in the last 3 months. The average price target is $19.00, with a high forecast of $23.00 and a low forecast of $17.00. The average price target represents a 116.89% upside from the last price of $8.76.
The current consensus among 3 contributing investment analysts is to buy stock in Verona Pharma. This Buy consensus rating has held steady for over two years.
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.